Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) insider Elizabeth Reed sold 20,000 shares of the business’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $45.00, for a total value of $900,000.00. Following the transaction, the insider directly owned 105,211 shares of the company’s stock, valued at $4,734,495. The trade was a 15.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Travere Therapeutics Stock Down 0.2%
TVTX stock traded down $0.10 during mid-day trading on Wednesday, reaching $44.70. The company had a trading volume of 2,390,035 shares, compared to its average volume of 2,890,153. The firm has a fifty day simple moving average of $32.59 and a 200 day simple moving average of $32.83. The company has a debt-to-equity ratio of 3.16, a quick ratio of 2.70 and a current ratio of 3.13. The company has a market capitalization of $4.16 billion, a price-to-earnings ratio of -194.33 and a beta of 1.13. Travere Therapeutics, Inc. has a fifty-two week low of $13.88 and a fifty-two week high of $48.61.
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last announced its quarterly earnings data on Monday, May 4th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.29. The business had revenue of $127.20 million during the quarter, compared to the consensus estimate of $136.23 million. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The business’s revenue for the quarter was up 55.6% on a year-over-year basis. During the same period in the previous year, the company posted ($0.47) earnings per share. Analysts forecast that Travere Therapeutics, Inc. will post -0.16 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Trending Headlines about Travere Therapeutics
Here are the key news stories impacting Travere Therapeutics this week:
- Positive Sentiment: TD Cowen raised its price target from $45 to $60 and kept a “buy” rating, implying meaningful upside vs. current levels — a bullish signal from a major sell‑side shop. TD Cowen price target raise
- Positive Sentiment: Wells Fargo upgraded its target to $50 and assigned an “overweight” rating, another near‑term positive catalyst supporting higher valuation expectations. Wells Fargo price target raise
- Neutral Sentiment: HC Wainwright reiterated a “Buy” and $57 target but trimmed FY2027–FY2030 EPS forecasts slightly (e.g., FY2027 cut from $0.71 to $0.60; FY2030 to $4.59 from $4.61). The firm still models substantial multi‑year growth, so this is more of a modest forecast tweak than a change in conviction. HC Wainwright note
- Neutral Sentiment: Earnings call transcript for Q1 2026 is available — recall Travere reported a year‑over‑year revenue gain and an EPS beat in the quarter, which helped underpin recent analyst upgrades. Review the transcript for management commentary on sparsentan commercialization and margin trajectory. Q1 2026 earnings transcript
- Negative Sentiment: Director Roy Baynes sold 9,750 shares (about $431k at the sale price) under a pre‑arranged Rule 10b5‑1 plan. Insider sales can be perceived negatively by the market despite the trading plan disclosure; monitor for any further insider activity. Insider sale filing
Wall Street Analysts Forecast Growth
TVTX has been the subject of several analyst reports. Guggenheim boosted their price target on shares of Travere Therapeutics from $54.00 to $56.00 and gave the stock a “buy” rating in a report on Friday, April 24th. JPMorgan Chase & Co. lowered their price target on shares of Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating for the company in a report on Wednesday, March 25th. Piper Sandler upgraded shares of Travere Therapeutics from a “neutral” rating to an “overweight” rating and set a $49.00 price target for the company in a report on Tuesday, April 14th. Wedbush boosted their price target on shares of Travere Therapeutics from $53.00 to $55.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Travere Therapeutics in a report on Wednesday, January 21st. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $47.83.
Get Our Latest Report on Travere Therapeutics
About Travere Therapeutics
Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.
The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.
Recommended Stories
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
